论文部分内容阅读
目的评估索利那新联合多沙唑嗪治疗前列腺增生症合并膀胱过度活动症的疗效。方法入组84例前列腺增生症合并膀胱过度活动症患者,分为治疗组,采用索利那新5mg,多沙唑嗪4mg,每日一次口服。对照组采用多沙唑嗪4mg,每日一次口服。为期4周。结果两组间基线资料比较差异无统计学差异。用药4周后,联合用药组及多沙唑嗪组IPSS评分及刺激症状评分均改善(P<0.05)。治疗后两组间比较显示:联合用药组IPSS评分的改善优于多沙唑嗪组(P<0.05),联合用药组刺激评分的改善优于多沙唑嗪组(P<0.05),治疗4周后两组间Qmax、残余尿差异无统计学意义(P>0.05)。结论索利那新联合多沙唑嗪治疗前列腺增生症合并膀胱过度活动症较单用多沙唑嗪更有效。
Objective To evaluate the efficacy of solifenacin combined with doxazosin in the treatment of benign prostatic hyperplasia with overactive bladder. Methods 84 cases of benign prostatic hyperplasia with overactive bladder patients were divided into treatment group, the use of solifenacin 5mg, doxazosin 4mg, once daily oral administration. Control group with doxazosin 4mg, once daily oral. For 4 weeks. Results There was no significant difference in baseline data between the two groups. After 4 weeks of treatment, the IPSS score and the irritation symptom scores of the combination group and doxazosin group were improved (P <0.05). After treatment, the comparison between two groups showed that the improvement of IPSS score was better than that of doxazosin group (P <0.05), and the improvement of stimulation score of combination group was better than that of doxazosin group (P <0.05) There was no significant difference in Qmax and residual urine between the two groups after week (P> 0.05). Conclusion Solifenac combined with doxazosin in the treatment of benign prostatic hyperplasia with overactive bladder is more effective than doxazosin alone.